Navigation Links
Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for Pulmonary Arterial Hypertension in the United States
Date:9/1/2009

ry vasodilation and inhibits platelet aggregation, among other benefits. Prostacyclin functions as a hormone, binding to receptors on smooth muscle cells, thereby affecting their function. Prostacyclin has multiple physiological effects, including vasodilation, inhibition of platelet aggregation, antiproliferation, anti-inflammation, and enhanced cardiac contractility.

In January 2007, Actelion announced the successful completion of its cash tender offer for shares of CoTherix, Inc., thereby strengthening its PAH franchise by adding Ventavis(R) to its product offerings in the United States. Bayer Schering Pharma - the inventor of Ventavis(R) - markets the drug as the first inhaled prostacyclin in Europe and other countries outside the US.

More information is available at www.4ventavis.com.

About Pulmonary Arterial Hypertension (PAH)

Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The function of the heart and lungs is severely compromised, manifested by a limited exercise capacity, and, ultimately, a reduced life expectancy. Approximately 100,000 people in Europe and the United States are afflicted with either primary or secondary forms of the disease related to conditions or tissue disorders that affect the lungs, such as scleroderma, lupus, HIV/AIDS or congenital heart disease.

PAH is associated with structural changes in both the pulmonary vasculature and the right ventricle. Recent advances (1) in the understanding of the pathogenic factors leading to the pulmonary vascular disease have led to the development of new therapies targeting specific pathways (the prostacyclin pathway; the endothelin pathway; and the nitric oxide pathway) (2).
'/>"/>

SOURCE Actelion Pharmaceuticals US, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
2. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
3. GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd.
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. Novozymes Launches Enzyme to Reduce Acrylamide in Food
6. Enova Medical Launches Exos Corporation
7. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
8. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
9. ThirdBiotech Networking Group Launches
10. BioReliance Launches Next-Generation Genotoxicity Screening Service
11. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... American Society for Reproductive Medicine (ASRM), a leading professional ... medicine. In his new role as treasurer, Dr. ... and will have a voice in furthering the mission ... ASRM since 1984 when he joined while conducting fellowship ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
... KENILWORTH, N.J., Dec. 10 The Board of Directors of Schering-Plough ... of 6.5 cents per common share. Payment will be made ... of business on Feb. 6, 2009. As of Sept. 30, ... , The Board of Directors today also declared ...
... Published in the Journal Blood for the American Society of ... SOMERSET, N.J., Dec. 10 Alfacell Corporation (Nasdaq: ... annual meeting abstracts in Blood (2008 112: Abstract ... and R-Amphinase (R-Amph) show anti-tumor activity in chronic lymphocytic leukemia ...
... December 10 /PRNewswire-FirstCall/,-- Oridion Systems Ltd. (SIX ... medical research project findings will be presented ... Care) Congress in,Anaheim, California. These studies confirm ... using Oridion Microstream(R) capnography technology,and clearly show ...
Cached Biology Technology:Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5Oridion Announces Significant Medical Research to be Presented at AARC Congress 2Oridion Announces Significant Medical Research to be Presented at AARC Congress 3
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, a ... Internet of Things (IoT), today announced the appointment of ... operating officer. Previously a strategic advisor to the firm, ... operations. Mr. Traynor is based out of the C-Labs ... reports to Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... The Quaking gene, first described as a mutation in ... tumor formation and protect humans from cancer. , ... the University of Wisconsin has shown that the Quaking ... a protein associated with GLI1, a cancer-causing oncogene highly ...
... Research Center at Oregon Health & Science University (OHSU) ... how stem cells become various kinds of brain cells. ... Parkinson's disease, brain and spinal cord injury, and other ... lost or damaged brain cells. The research is published ...
... olive oil, which have antioxidant, anti-inflammatory and anti-clotting ... the so-called Mediterranean Diet, according to a new ... the Journal of the American College of Cardiology. ... of the Mediterranean diet on cardiovascular disease and ...
Cached Biology News:Researchers discover new form of cancer gene regulation 2Researchers discover new form of cancer gene regulation 3OHSU discovery sheds light into how stem cells become brain cells 2Phenolic compounds may explain Mediterranean diet benefits 2Phenolic compounds may explain Mediterranean diet benefits 3
... These handy dispensers save space ... wipers, hats, and other garb. ... storage bins for small parts ... manufacturing. Clear acrylic. Many other ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known arabidopsis microRNAs ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known maize microRNAs ...
...
Biology Products: